Bristol Myers Squibb BMY recently announced a strategic collaboration agreement with BioNTech BNTX for the global ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

Bristol-Myers Squibb and BioNTech announced a major deal worth up to $11 billion in early June. Click here to find out why I ...

Bristol Myers and BioNTech are teaming up to develop and commercialize BNT327, a cancer therapy with blockbuster ambition.

Sanofi picked up Blueprint Medicines in a deal worth up to $9.5 billion. Bristol Myers Squibb will pay $1.5 billion upfront ...

Marketed as BNT327, the PD-L1xVEGF-A bispecific antibody has the potential to become what the involved parties believe is a ...

Bristol-Myers Squibb has teamed up with BioNTech to co-develop a bispecific antibody, BNT327, targeting multiple solid tumors ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

CHICAGO -- Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with ...

Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of ...

Bristol Myers Squibb and BioNTech to co-develop cancer immunotherapy BNT327 in a deal worth up to $11.1 billion.